Background: PD-L1 expression on tumor predicts benefit to immune checkpoint inhibitors (ICI) in patients with advanced NSCLC. However, there are a significant number of patients whose tumor test positive for PD-L1 expression that do not derive benefit from ICI, suggesting the existence of intrinsic resistance mechanisms. PD-L1 blockade aims to trigger tumor cell recognition and lysis by CD8+ T cells, but this process requires concordant expression of MHC I by tumor cells. Recently, MHC I negativity was observed in 49% of patients with lung carcinoma, and correlated with a lack of CD8+ T cell infiltration, emphasizing the importance of screening for MHC I in combination with PD-L1. Method: For the purposes of both screening and the detection of acquired resistance, we developed a minimally invasive diagnostic test using Circulating Tumor Cells (CTCs). CTCs were captured and stained on the ExtractMax system (Gilson, Inc.) with Exclusion-Based Sample Processing (ESP) technology (Salus Discovery, LLC). With automation, the ExtractMax simplifies complex multi-step procedures, reduces variability, and ensures gentle manipulation of rare cell targets for optimal yield and viability. Invasive diagnostic test using Circulating Tumor Cells (CTCs). CTCs were captured and stained on the ExtractMax system (Gilson, Inc.) with Exclusion-Based Sample Processing (ESP) technology (Salus Discovery, LLC). With automation, the ExtractMax simplifies complex multi-step procedures, reduces variability, and ensures gentle manipulation of rare cell targets for optimal yield and viability. Results: A range of PD-L1 and MHC I expression levels were detected on CTCs captured from a cohort of patients with NSCLC, with two patients showing no MHC 1 expression and all others with heterogeneous expression of MHC 1. PD-L1 expression was variable across all samples tested with subset of patients with PD-L1 positive CTCs but MHC I negative, suggesting intrinsic resistance to PD-L1 targeted therapies. Conclusion: This data supports the feasibility of using an automated CTC processing system to detect and monitor PD-L1 and MHC I expression in patients with NSCLC. Ongoing efforts include expanding this patient cohort in larger clinical trials and transitioning this test into a clinical laboratory testing facility for regulatory approval and use as a clinically actionable diagnostic tool. Keywords: NSCLC, immunotherapy, PD-L1, CTCs
